Erasca Reports First Quarter 2025 Business Updates and Financial Results
Provided By GlobeNewswire
Last update: May 13, 2025
Early entry of RAS-targeting franchise into clinic enabled by strong execution
Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026
Read more at globenewswire.com
